Does the media favor CRL or ICLR?

In the previous week, Icon had 2 more articles in the media than Charles River Laboratories International. MarketBeat recorded 6 mentions for Icon and 4 mentions for Charles River Laboratories International. Icon's average media sentiment score of 0.96 beat Charles River Laboratories International's score of 0.77 indicating that Icon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Icon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TECH or CRL?

In the previous week, Bio-Techne and Bio-Techne both had 4 articles in the media. Bio-Techne's average media sentiment score of 0.82 beat Charles River Laboratories International's score of 0.77 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRL or IQV?

In the previous week, IQVIA had 12 more articles in the media than Charles River Laboratories International. MarketBeat recorded 16 mentions for IQVIA and 4 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 1.32 beat Charles River Laboratories International's score of 0.77 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRL or RVTY?

In the previous week, Revvity had 1 more articles in the media than Charles River Laboratories International. MarketBeat recorded 5 mentions for Revvity and 4 mentions for Charles River Laboratories International. Revvity's average media sentiment score of 0.78 beat Charles River Laboratories International's score of 0.77 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Charles River Laboratories International (CRL) Competitors

$219.91 -4.44 (-1.98%)

Closing price 07/20/2026 03:59 PM Eastern

Extended Trading

$219.78 -0.13 (-0.06%)

As of 07/20/2026 07:34 PM Eastern

Compare

CRL vs. ICLR, TECH, A, IQV, and RVTY

Should you buy Charles River Laboratories International stock or one of its competitors? MarketBeat compares Charles River Laboratories International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Charles River Laboratories International include Icon (ICLR), Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), and Revvity (RVTY). These companies are all part of the "medical" sector.

How does Charles River Laboratories International compare to Icon?

Charles River Laboratories International (NYSE:CRL) and Icon (NASDAQ:ICLR) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Icon has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.64	-$144.34M	-$3.76	N/A
Icon	$8.25B	1.54	$229.34M	$5.62	29.57

In the previous week, Icon had 2 more articles in the media than Charles River Laboratories International. MarketBeat recorded 6 mentions for Icon and 4 mentions for Charles River Laboratories International. Icon's average media sentiment score of 0.96 beat Charles River Laboratories International's score of 0.77 indicating that Icon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Icon has a net margin of 5.35% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Icon	5.35%	8.73%	4.96%

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 44.0% of Icon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Charles River Laboratories International currently has a consensus price target of $220.75, suggesting a potential upside of 0.38%. Icon has a consensus price target of $173.19, suggesting a potential upside of 4.22%. Given Icon's higher possible upside, analysts clearly believe Icon is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Icon	3 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.33

Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Icon has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Icon beats Charles River Laboratories International on 9 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Bio-Techne currently has a consensus target price of $68.08, indicating a potential downside of 4.97%. Charles River Laboratories International has a consensus target price of $220.75, indicating a potential upside of 0.38%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

Bio-Techne has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

In the previous week, Bio-Techne and Bio-Techne both had 4 articles in the media. Bio-Techne's average media sentiment score of 0.82 beat Charles River Laboratories International's score of 0.77 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.20	$73.40M	$0.69	103.83
Charles River Laboratories International	$4.02B	2.64	-$144.34M	-$3.76	N/A

Summary

Bio-Techne beats Charles River Laboratories International on 8 of the 14 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Charles River Laboratories International (NYSE:CRL) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Agilent Technologies has a net margin of 19.55% compared to Charles River Laboratories International's net margin of -4.59%. Agilent Technologies' return on equity of 24.33% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Agilent Technologies	19.55%	24.33%	12.99%

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Charles River Laboratories International presently has a consensus target price of $220.75, indicating a potential upside of 0.38%. Agilent Technologies has a consensus target price of $159.35, indicating a potential upside of 22.07%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.64	-$144.34M	-$3.76	N/A
Agilent Technologies	$6.95B	5.31	$1.30B	$4.98	26.21

In the previous week, Agilent Technologies had 8 more articles in the media than Charles River Laboratories International. MarketBeat recorded 12 mentions for Agilent Technologies and 4 mentions for Charles River Laboratories International. Agilent Technologies' average media sentiment score of 1.20 beat Charles River Laboratories International's score of 0.77 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agilent Technologies beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, IQVIA had 12 more articles in the media than Charles River Laboratories International. MarketBeat recorded 16 mentions for IQVIA and 4 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 1.32 beat Charles River Laboratories International's score of 0.77 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.64	-$144.34M	-$3.76	N/A
IQVIA	$16.31B	2.09	$1.36B	$8.07	25.32

IQVIA has a net margin of 8.33% compared to Charles River Laboratories International's net margin of -4.59%. IQVIA's return on equity of 30.50% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
IQVIA	8.33%	30.50%	6.53%

Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 1.7% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Charles River Laboratories International presently has a consensus target price of $220.75, suggesting a potential upside of 0.38%. IQVIA has a consensus target price of $225.71, suggesting a potential upside of 10.46%. Given IQVIA's stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

IQVIA beats Charles River Laboratories International on 12 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Charles River Laboratories International (NYSE:CRL) and Revvity (NYSE:RVTY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Revvity has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.64	-$144.34M	-$3.76	N/A
Revvity	$2.86B	4.16	$241.20M	$2.09	50.99

Revvity has a net margin of 8.26% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Revvity	8.26%	8.00%	4.83%

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Revvity has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Revvity had 1 more articles in the media than Charles River Laboratories International. MarketBeat recorded 5 mentions for Revvity and 4 mentions for Charles River Laboratories International. Revvity's average media sentiment score of 0.78 beat Charles River Laboratories International's score of 0.77 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International currently has a consensus price target of $220.75, suggesting a potential upside of 0.38%. Revvity has a consensus price target of $108.92, suggesting a potential upside of 2.21%. Given Revvity's higher possible upside, analysts clearly believe Revvity is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Revvity	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Charles River Laboratories International and Revvity tied by winning 8 of the 16 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$10.81B	$9.65B	$6.89B	$23.42B
Dividend Yield	N/A	1.60%	2.67%	4.16%
P/E Ratio	-58.49	26.62	27.06	30.65
Price / Sales	2.64	18.93	517.51	20.36
Price / Cash	10.22	15.03	26.68	18.81
Price / Book	3.42	6.14	10.66	4.74
Net Income	-$144.34M	$179.69M	$3.60B	$1.07B
7 Day Performance	-5.08%	-0.98%	-1.23%	-0.42%
1 Month Performance	18.76%	4.88%	1.10%	0.69%
1 Year Performance	46.90%	13.70%	23.65%	16.45%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	1.7169 of 5 stars	$219.91 -2.0%	$220.75 +0.4%	+42.3%	$10.81B	$4.02B	N/A	19,700	Analyst Downgrade
ICLR Icon	3.3174 of 5 stars	$165.47 -1.9%	$173.19 +4.7%	+15.8%	$12.92B	$8.25B	29.44	40,100
TECH Bio-Techne	2.3937 of 5 stars	$70.96 +0.5%	$67.79 -4.5%	+37.7%	$11.06B	$1.22B	102.84	3,100
A Agilent Technologies	4.9727 of 5 stars	$128.77 -1.8%	$160.88 +24.9%	+14.5%	$37.04B	$6.95B	25.86	18,100	Positive News
IQV IQVIA	4.2651 of 5 stars	$203.87 -2.1%	$223.88 +9.8%	+27.0%	$34.75B	$16.31B	25.26	93,000	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Which has higher valuation & earnings, CRL or ICLR?

Does the media favor CRL or ICLR?

Is CRL or ICLR more profitable?

Do institutionals & insiders hold more shares of CRL or ICLR?

Do analysts rate CRL or ICLR?

Which has more volatility and risk, CRL or ICLR?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Do analysts prefer TECH or CRL?

Which has more volatility and risk, TECH or CRL?

Does the media favor TECH or CRL?

Do insiders and institutionals believe in TECH or CRL?

Is TECH or CRL more profitable?

Which has preferable valuation and earnings, TECH or CRL?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Is CRL or A more profitable?

Which has more risk & volatility, CRL or A?

Do analysts rate CRL or A?

Do institutionals and insiders have more ownership in CRL or A?

Which has higher valuation and earnings, CRL or A?

Does the media refer more to CRL or A?

Summary

How does Charles River Laboratories International compare to IQVIA?

Does the media favor CRL or IQV?

Which has higher earnings and valuation, CRL or IQV?

Is CRL or IQV more profitable?

Which has more risk and volatility, CRL or IQV?

Do insiders & institutionals have more ownership in CRL or IQV?

Do analysts recommend CRL or IQV?

Summary

How does Charles River Laboratories International compare to Revvity?

Which has stronger earnings and valuation, CRL or RVTY?

Is CRL or RVTY more profitable?

Do institutionals and insiders hold more shares of CRL or RVTY?

Which has more risk and volatility, CRL or RVTY?

Does the media refer more to CRL or RVTY?

Do analysts prefer CRL or RVTY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools